David Toung On Johnson & Johnson Earnings

David Toung says the FDA panel is not expected to approve the resumption of JNJ's vaccine this week. For the company, the vaccine issue may not be a material concern to the company's earnings and revenue Medical devices are expected to show robust growth due to elective procedures and consumer health products are expected to show improving sales.

Market On Close

20 Apr 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US

David Toung On Johnson & Johnson Earnings

David Toung says the FDA panel is not expected to approve the resumption of JNJ's vaccine this week. For the company, the vaccine issue may not be a material concern to the company's earnings and revenue Medical devices are expected to show robust growth due to elective procedures and consumer health products are expected to show improving sales.

Market On Close

20 Apr 2021

ON AIR
7:00 am
Market Overtime
replay

Get Market Minute

Daily insights for every investor

FOLLOW US